Levin V A, Hoffman W F, Pischer T L, Seager M L, Boldrey E B, Wilson C B
Cancer Treat Rep. 1978 Dec;62(12):2071-6.
Twenty-nine patients with recurrent malignant brain tumors were evaluated. BCNU (180 mg/m2) was administered iv on Day 1 and 5-fluorouracil (1 g/m2/day) was given by continuous infusion on Days 15--17. Courses were repeated every 6 weeks until tumor progression occurred. Before each course, a neurologic examination and radionuclide and computerized tomographic scans were performed. Response and progression were defined as improvement or deterioration, respectively, in at least two of the three tests. Nine of 29 patients (31%) responded to therapy, five of 29 (17%) showed progression, and 15 of 29 (52%) had disease stability. The estimated median time to progression was 27 weeks for all patients, 34 weeks for the response group, and 25 weeks for the stable group. Of all 29 patients, 24 (83%) had tumor progression arrested; 40% with response and 6% with stable disease were continuing therapy after 1 year. The stable disease group was larger and the duration of stability was longer than that seen in previous studies. Evaluated by time to progression, a BCNU-5-fluorouracil combination is superior to either BCNU alone or a BCNU-procarbazine combination.
对29例复发性恶性脑肿瘤患者进行了评估。第1天静脉注射卡莫司汀（180mg/m²），第15 - 17天持续输注5-氟尿嘧啶（1g/m²/天）。每6周重复疗程，直至肿瘤进展。每个疗程前，进行神经系统检查、放射性核素检查和计算机断层扫描。缓解和进展分别定义为三项检查中至少两项出现改善或恶化。29例患者中有9例（31%）对治疗有反应，29例中有5例（17%）出现进展，29例中有15例（52%）病情稳定。所有患者的估计中位进展时间为27周，反应组为34周，稳定组为25周。29例患者中，24例（83%）肿瘤进展得到控制；反应组40%和病情稳定组6%在1年后仍在继续治疗。病情稳定组比以往研究中的更大，且稳定持续时间更长。按进展时间评估，卡莫司汀-5-氟尿嘧啶联合方案优于单独使用卡莫司汀或卡莫司汀-丙卡巴肼联合方案。
